| ECL |
Report |
Adj. Diluted EPS (Q2 2026) |
BEAT |
pred ~$2.12 vs. cons $2.08 (+1.9%) |
MEDIUM |
| ECL |
Report |
Organic Sales Growth (Q2 2026) |
BEAT |
pred ~5.1% vs. cons 4.77% (+33bp) |
MEDIUM |
| ECL |
Report |
Organic OI Margin (Q2 2026) |
IN-LINE |
pred ~18.7% vs. cons 18.67% (+3bp) |
MEDIUM |
| ECL |
Guide |
FY2026 Adj. EPS (FY2026) |
UNCHANGED |
guide $8.03-$8.23 reaffirmed vs. cons $8.19 |
HIGH |
| ECL |
Guide |
Q3 2026 Adj. EPS (Q3 2026) |
BETTER |
guide ~$2.15 vs. cons $2.08 (+3.4%) |
MEDIUM |
| ECL |
Guide |
H2 Organic Sales Growth (H2 2026) |
BETTER |
guide 6-7% reaffirmed vs. cons ~4.8% Q3 |
MEDIUM |
| ECL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| ECL |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — sell-side revises Q3/FY estimates up on Q3 guide above consensus; consistent with all 3 prior Archetype A quarters |
MEDIUM |